Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options.
Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells.
Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.
Company Details
- Employees
- 29
- Founded
- -
- Address
- 3675 Market St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://verismotherapeutics.com/
- HQ
- Philadelphia, Pennsylvania
Verismo Therapeutics Questions
Verismo Therapeutics's website is https://verismotherapeutics.com/
Verismo Therapeutics's LinkedIn profile is https://www.linkedin.com/company/verismo-therapeutics
Verismo Therapeutics has
29 employees.
View email and phone details for 29
employees at Verismo Therapeutics.
Verismo Therapeutics's industry is
Biotechnology Research
Verismo Therapeutics's top competitors are
Passage Bio,
Cabaletta Bio,
Spark Therapeutics, Inc.,
Swanbio Therapeutics,
Carisma Therapeutics,
Kyverna Therapeutics,
Adaptimmune,
Century Therapeutics, Inc,
Bluewhale Bio,
Interius Biotherapeutics.
Verismo Therapeutics's categories are Biotechnology Research
Verismo Therapeutics's founding year is 2020
